NUTEX HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
Nutex Health (NASDAQ: NUTX) reported strong financial results for FY2024, with total revenue reaching $479.9 million, up 93.8% from $247.6 million in 2023. The company achieved a significant turnaround with net income of $52.2 million compared to a net loss of $45.8 million in 2023, resulting in diluted EPS of $9.71.
Key highlights include EBITDA of $98.4 million and Adjusted EBITDA of $123.7 million, representing a 1,045.4% increase from 2023. The Hospital Division recorded 168,388 total visits, up 16.9% year-over-year. The company's arbitration efforts through the Independent Dispute Resolution process contributed significantly, resulting in approximately $169.7 million more in revenue compared to 2023.
As of December 31, 2024, Nutex Health maintained a strong balance sheet with total assets of $655.3 million, including $43.6 million in cash and cash equivalents, and long-term debt of $22.5 million. The company operates 24 micro hospitals and hospital outpatient departments across 11 states.
Nutex Health (NASDAQ: NUTX) ha riportato risultati finanziari solidi per l'anno fiscale 2024, con ricavi totali che hanno raggiunto 479,9 milioni di dollari, in aumento del 93,8% rispetto ai 247,6 milioni di dollari del 2023. L'azienda ha ottenuto un notevole cambiamento con un utile netto di 52,2 milioni di dollari rispetto a una perdita netta di 45,8 milioni di dollari nel 2023, portando a un utile per azione diluito di 9,71 dollari.
I punti salienti includono un EBITDA di 98,4 milioni di dollari e un EBITDA rettificato di 123,7 milioni di dollari, che rappresenta un aumento del 1.045,4% rispetto al 2023. La Divisione Ospedaliera ha registrato un totale di 168.388 visite, con un incremento del 16,9% rispetto all'anno precedente. Gli sforzi di arbitrato dell'azienda attraverso il processo di Risoluzione delle Controversie Indipendente hanno contribuito in modo significativo, portando a circa 169,7 milioni di dollari in più di ricavi rispetto al 2023.
Al 31 dicembre 2024, Nutex Health ha mantenuto un bilancio solido con attività totali di 655,3 milioni di dollari, inclusi 43,6 milioni di dollari in contante e equivalenti, e debito a lungo termine di 22,5 milioni di dollari. L'azienda gestisce 24 micro ospedali e reparti ospedalieri ambulatoriali in 11 stati.
Nutex Health (NASDAQ: NUTX) reportó resultados financieros sólidos para el año fiscal 2024, con ingresos totales que alcanzaron 479,9 millones de dólares, un aumento del 93,8% en comparación con los 247,6 millones de dólares en 2023. La compañía logró un cambio significativo con un ingreso neto de 52,2 millones de dólares en comparación con una pérdida neta de 45,8 millones de dólares en 2023, resultando en una utilidad por acción diluida de 9,71 dólares.
Los aspectos más destacados incluyen un EBITDA de 98,4 millones de dólares y un EBITDA ajustado de 123,7 millones de dólares, lo que representa un aumento del 1.045,4% en comparación con 2023. La División Hospitalaria registró 168.388 visitas totales, un aumento del 16,9% interanual. Los esfuerzos de arbitraje de la compañía a través del proceso de Resolución de Disputas Independiente contribuyeron significativamente, resultando en aproximadamente 169,7 millones de dólares más en ingresos en comparación con 2023.
Al 31 de diciembre de 2024, Nutex Health mantuvo un balance sólido con activos totales de 655,3 millones de dólares, incluyendo 43,6 millones de dólares en efectivo y equivalentes, y una deuda a largo plazo de 22,5 millones de dólares. La compañía opera 24 micro hospitales y departamentos ambulatorios hospitalarios en 11 estados.
Nutex Health (NASDAQ: NUTX)는 2024 회계연도에 대해 강력한 재무 결과를 보고했으며, 총 수익은 4억 7,990만 달러에 달해 2023년의 2억 4,760만 달러에서 93.8% 증가했습니다. 회사는 2023년의 4,580만 달러 순손실에 비해 5,220만 달러의 순이익을 달성하며 상당한 전환을 이루었고, 희석 주당순이익은 9.71달러에 달했습니다.
주요 하이라이트로는 9,840만 달러의 EBITDA와 1억 2,370만 달러의 조정 EBITDA가 있으며, 이는 2023년 대비 1,045.4% 증가한 수치입니다. 병원 부문은 총 168,388회의 방문을 기록하며 전년 대비 16.9% 증가했습니다. 회사의 독립 분쟁 해결 프로세스를 통한 중재 노력은 2023년 대비 약 1억 6,970만 달러의 추가 수익을 가져오는 데 크게 기여했습니다.
2024년 12월 31일 기준으로 Nutex Health는 총 자산 6억 5,530만 달러를 유지하며, 이 중 4,360만 달러는 현금 및 현금성 자산이고, 장기 부채는 2,250만 달러입니다. 회사는 11개 주에서 24개의 마이크로 병원과 병원 외래 진료 부서를 운영하고 있습니다.
Nutex Health (NASDAQ: NUTX) a annoncé de solides résultats financiers pour l'exercice 2024, avec un chiffre d'affaires total atteignant 479,9 millions de dollars, soit une augmentation de 93,8 % par rapport aux 247,6 millions de dollars de 2023. L'entreprise a réalisé un retournement significatif avec un bénéfice net de 52,2 millions de dollars comparé à une perte nette de 45,8 millions de dollars en 2023, ce qui a entraîné un bénéfice par action dilué de 9,71 dollars.
Les points clés incluent un EBITDA de 98,4 millions de dollars et un EBITDA ajusté de 123,7 millions de dollars, représentant une augmentation de 1.045,4 % par rapport à 2023. La division des hôpitaux a enregistré 168.388 visites au total, soit une augmentation de 16,9 % par rapport à l'année précédente. Les efforts d'arbitrage de l'entreprise grâce au processus de résolution indépendante des différends ont contribué de manière significative, entraînant environ 169,7 millions de dollars de revenus supplémentaires par rapport à 2023.
Au 31 décembre 2024, Nutex Health maintenait un bilan solide avec des actifs totaux de 655,3 millions de dollars, y compris 43,6 millions de dollars en espèces et équivalents, et une dette à long terme de 22,5 millions de dollars. L'entreprise gère 24 micro-hôpitaux et départements ambulatoires hospitaliers dans 11 États.
Nutex Health (NASDAQ: NUTX) berichtete über starke Finanzergebnisse für das Geschäftsjahr 2024, mit einem Gesamtumsatz von 479,9 Millionen Dollar, was einem Anstieg von 93,8% gegenüber 247,6 Millionen Dollar im Jahr 2023 entspricht. Das Unternehmen erzielte eine signifikante Wende mit einem Nettoeinkommen von 52,2 Millionen Dollar im Vergleich zu einem Nettoverlust von 45,8 Millionen Dollar im Jahr 2023, was zu einem verwässerten Gewinn pro Aktie von 9,71 Dollar führte.
Wichtige Highlights sind ein EBITDA von 98,4 Millionen Dollar und ein bereinigtes EBITDA von 123,7 Millionen Dollar, was einen Anstieg von 1.045,4% im Vergleich zu 2023 darstellt. Die Krankenhausabteilung verzeichnete insgesamt 168.388 Besuche, was einem Anstieg von 16,9% im Jahresvergleich entspricht. Die Schlichtungsbemühungen des Unternehmens durch den unabhängigen Streitbeilegungsprozess trugen erheblich dazu bei, was zu etwa 169,7 Millionen Dollar mehr Umsatz im Vergleich zu 2023 führte.
Zum 31. Dezember 2024 wies Nutex Health eine solide Bilanz mit Gesamtvermögen von 655,3 Millionen Dollar auf, einschließlich 43,6 Millionen Dollar in bar und liquiden Mitteln sowie langfristigen Schulden von 22,5 Millionen Dollar. Das Unternehmen betreibt 24 Mikkrankenhäuser und ambulante Krankenhausabteilungen in 11 Bundesstaaten.
- Revenue surge of 93.8% to $479.9 million in 2024
- Turnaround to net income of $52.2 million from previous year's loss
- Significant EBITDA improvement to $98.4 million from -$22.5 million
- Hospital visits increased 16.9% year-over-year
- Strong cash position of $43.6 million with relatively low debt of $22.5 million
- Successful arbitration efforts leading to $169.7 million additional revenue
- High dependence on arbitration process for revenue growth (73.1% of increase)
- Significant non-cash expenses including $16.6 million in stock-based compensation
- Asset and goodwill impairments totaling $7.1 million
Insights
Nutex Health's Q4 and FY 2024 results reveal an extraordinary financial transformation, with the company swinging from substantial losses to significant profitability. The
The primary catalyst behind this turnaround appears to be the company's successful arbitration efforts through the Independent Dispute Resolution process, which generated approximately
Beyond the arbitration success, Nutex demonstrated organic growth with hospital visits increasing
The company's profitability metrics show exceptional improvement, with operating income reaching
This performance demonstrates that Nutex's physician-led, integrated healthcare delivery model focusing on micro-hospitals and outpatient departments is gaining significant traction, with the financial results validating both its operational strategy and revenue cycle management efforts.
FULL YEAR 2024 HIGHLIGHTS:
- TOTAL REVENUE OF
$479.9 MILLION $247.6 MILLION 93.8% - NET INCOME OF
$52.2 MILLION $45.8 MILLION - DILUTED EPS OF
$9.71 $(10.39) - EBITDA OF
$98.4 MILLION $(22.5) MILLION - ADJUSTED EBITDA OF
$123.7 MILLION $10.8 MILLION 045.4% - NET CASH FROM OPERATING ACTIVITIES OF
$23.2 MILLION - COMPANY BELIEVES ITS ARBITRATION EFFORTS, THROUGH THE INDEPENDENT DISPUTE RESOLUTION (IDR) PROCESS, HAS RESULTED IN MORE EQUITABLE PAYMENTS
Financial highlights for the year ended December 31, 2024:
- Total revenue increased
$232.3 million $479.9 million $247.6 million 93.8% . Of this revenue growth, revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by56.6% in 2024 compared to 2023. - The arbitration process resulted in approximately
$169.7 million 73.1% of the$232.3 million $169.7 million $68.9 million $70.5 million $30.3 million - Operating income for the year ended December 31, 2024 was
$130.6 million $31.8 million $162.4 million - Net income attributable to Nutex Health of
$52.2 million $45.8 million $52.2 million $25.3 million $16.6 million $3.9 million $3.2 million $1.6 million $45.8 million $33 million $2.8 million $29.1 million $1.1 million - EBITDA attributable to Nutex Health of
$98.4 million $(22.5) million - Adjusted EBITDA attributable to Nutex Health of
$123.7 million $10.8 million 045.4% . - Total visits at the Hospital Division were 168,388 for the year ended December 31, 2024, as compared to 144,058 for the same period in 2023, an increase of 24,330 or
16.9% . Of this visit growth, visits at mature hospitals increased by6.5% in the year ended December 31, 2024 compared to the same period in 2023. - Net cash from operating activities of
$23.2 million - As of December 31, 2024, the Company had total assets of
$655.3 million $43.6 million $22.5 million
Financial highlights for the three months ended December 31, 2024:
- Total revenue of
$257.6 million $69.7 million $187.9 million 269.6% ). Of this revenue growth, revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by175.6% in 2024 compared to the same period in 2023. - The arbitration process resulted in approximately
$169.7 million 90.3% of the$187.9 million $169.7 million $68.9 million $70.5 million $30.3 million - Operating income (including the negative impact of a
$14.7 million $114.2 million $26.1 million $140.3 million - Net income attributable to Nutex Health of
$61.7 million $31.7 million $61.7 million $0.5 million $14.7 million - EBITDA attributable to Nutex Health of
$78.4 million $(27.7) million - Adjusted EBITDA attributable to Nutex Health of
$93.6 million $3.1 million 919.4% . - Total visits at the Hospital Division were 45,444 for the fourth quarter 2024, as compared to 41,381 for the fourth quarter 2023, an increase of 4,063 or
9.8% . Of this visit growth, visits at mature hospitals increased by3.1% in 2024 compared to the same period in 2023.
Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.
"We are pleased to report record annual revenues, net income and solid free cash flows, as well as impressive margin expansion as a result of our continued focus on revenue growth while controlling our costs and still opening four hospitals in 2024," stated Jon Bates, Chief Financial Officer of Nutex Health.
"In 2024, Nutex Health achieved significant operational improvements across all key metrics. Total hospital division visits increased by
"Nutex Health delivered healthy year-end and fourth quarter financial and operational results last year. The arbitration initiative that we began in July 2024 is generating higher reimbursement amounts per visit this year and is more in line with a fair market rate. We would like to thank our dedicated teams of physicians, nurses and all our other team members for continuing to deliver for our patients. We enter 2025 with great momentum and look forward to continuing our strong financial and operational performance," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.
For more details on the Company's Fourth Quarter 2024 financial results, please refer to our Annual Report on Form 10-K filed with the
NUTEX HEALTH INC. CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||||
December 31, | ||||||
2024 | 2023 | |||||
Assets | ||||||
Current assets: | ||||||
Cash and cash equivalents | $ | 43,581,412 | $ | 22,002,056 | ||
Accounts receivable | 232,449,226 | 58,624,301 | ||||
Accounts receivable - related parties | 3,602,189 | 4,152,068 | ||||
Inventories | 2,849,814 | 3,390,584 | ||||
Prepaid expenses and other current assets | 9,996,244 | 2,679,394 | ||||
Total current assets | 292,478,885 | 90,848,403 | ||||
Property and equipment, net | 77,932,744 | 81,387,649 | ||||
Operating right-of-use assets | 27,871,830 | 11,853,082 | ||||
Financing right-of-use assets | 218,889,351 | 176,146,329 | ||||
Intangible assets, net | 15,530,281 | 20,512,636 | ||||
Goodwill, net | 13,918,719 | 17,066,263 | ||||
Deferred tax assets | 7,987,236 | - | ||||
Other assets | 711,347 | 431,135 | ||||
Total assets | $ | 655,320,393 | $ | 398,245,497 | ||
Liabilities and Equity | ||||||
Current liabilities: | ||||||
Accounts payable | $ | 9,613,821 | $ | 18,899,196 | ||
Accounts payable - related parties | 4,345,138 | 6,382,197 | ||||
Lines of credit | 3,554,029 | 3,371,676 | ||||
Current portion of long-term debt | 14,395,457 | 10,808,721 | ||||
Operating lease liabilities, current portion | 2,079,940 | 1,579,987 | ||||
Financing lease liabilities, current portion | 7,704,873 | 4,315,979 | ||||
Accrued arbitration expenses | 47,741,815 | - | ||||
Accrued income tax expense | 25,989,262 | - | ||||
Accrued expenses and other current liabilities | 25,441,790 | 12,955,296 | ||||
Total current liabilities | 140,866,125 | 58,313,052 | ||||
Long-term debt, net | 22,465,896 | 26,314,733 | ||||
Operating lease liabilities, net | 30,617,399 | 15,479,639 | ||||
Financing lease liabilities, net | 259,479,096 | 213,886,213 | ||||
Deferred tax liabilities | - | 5,145,754 | ||||
Total liabilities | 453,428,516 | 319,139,391 | ||||
Commitments and contingencies (Note 10) | ||||||
Equity: | ||||||
Common stock, | 5,511 | 4,511 | ||||
Additional paid-in capital | 503,232,609 | 470,521,218 | ||||
Accumulated deficit | (356,893,371) | (409,072,539) | ||||
Nutex Health Inc. equity | 146,344,749 | 61,453,190 | ||||
Noncontrolling interests | 55,547,128 | 17,652,916 | ||||
Total equity | 201,891,877 | 79,106,106 | ||||
Total liabilities and equity | $ | 655,320,393 | $ | 398,245,497 | ||
NUTEX HEALTH INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | ||||||||||||
Three months ended December 31 | Year ended December 31 | |||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||
Revenue: | ||||||||||||
Hospital division | $ | 249,696,907 | $ | 62,585,167 | $ | 449,063,683 | $ | 218,070,397 | ||||
Population health management division | 7,920,809 | 7,084,306 | 30,884,950 | 29,575,919 | ||||||||
Total revenue | 257,617,716 | 69,669,473 | 479,948,633 | 247,646,316 | ||||||||
Operating costs and expenses: | ||||||||||||
Payroll | 32,277,720 | 28,807,419 | 117,527,022 | 108,377,938 | ||||||||
Contract services | 68,275,505 | 14,377,128 | 100,757,191 | 42,349,982 | ||||||||
Medical supplies | 2,392,577 | 3,402,926 | 15,285,481 | 14,151,140 | ||||||||
Depreciation and amortization | 5,280,488 | 4,682,724 | 18,971,972 | 17,591,572 | ||||||||
Other | 7,765,372 | 5,185,964 | 31,145,690 | 30,401,513 | ||||||||
Total operating costs and expenses | 115,991,662 | 56,456,161 | 283,687,356 | 212,872,145 | ||||||||
Gross profit | 141,626,054 | 13,213,312 | 196,261,277 | 34,774,171 | ||||||||
Corporate and other costs: | ||||||||||||
Facilities closing costs | - | - | - | 217,266 | ||||||||
Acquisition costs | - | - | - | 43,464 | ||||||||
Stock-based compensation | 14,680,454 | 637,159 | 16,631,898 | 2,835,971 | ||||||||
Impairment of assets | (11,640) | 29,082,203 | 3,887,216 | 29,082,203 | ||||||||
Impairment of goodwill | - | 1,139,297 | 3,197,391 | 1,139,297 | ||||||||
General and administrative expenses | 12,747,842 | 8,499,550 | 41,923,972 | 33,229,718 | ||||||||
Total corporate and other costs | 27,416,656 | 39,358,209 | 65,640,477 | 66,547,919 | ||||||||
Operating income (loss) | 114,209,398 | (26,144,897) | 130,620,800 | (31,773,748) | ||||||||
Interest expense, net | 5,052,081 | 4,236,553 | 19,932,015 | 16,317,869 | ||||||||
Loss on warrant liability | 536,264 | - | 1,608,973 | - | ||||||||
Other expense (income) | 43,119 | 328,461 | (668,930) | 399,182 | ||||||||
Income (loss) before taxes | 108,577,934 | (30,709,911) | 109,748,742 | (48,490,799) | ||||||||
Income tax expense (benefit) | 8,608,746 | (2,998,554) | 14,476,821 | (5,067,084) | ||||||||
Net income (loss) | 99,969,188 | (27,711,357) | 95,271,921 | (43,423,715) | ||||||||
Less: net income attributable to noncontrolling interests | 38,273,584 | 3,906,540 | 43,092,753 | 2,362,899 | ||||||||
Net income (loss) attributable to Nutex Health Inc. | $ | 61,695,604 | $ | (31,617,897) | $ | 52,179,168 | $ | (45,786,614) | ||||
Earnings (loss) per common share | ||||||||||||
Basic | $ | 11.83 | $ | (7.47) | $ | 10.25 | $ | (10.39) | ||||
Diluted | $ | 11.12 | $ | (7.47) | $ | 9.71 | $ | (10.39) | ||||
NUTEX HEALTH INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | |||||||||
Year ended December 31, | |||||||||
2024 | 2023 | 2022 | |||||||
Cash flows from operating activities: | |||||||||
Net income (loss) | $ | 95,271,921 | $ | (43,423,715) | $ | (432,739,618) | |||
Adjustment to reconcile net income (loss) to net cash from operating activities: | |||||||||
Depreciation and amortization | 18,971,972 | 17,591,572 | 13,131,374 | ||||||
Impairment of assets | 3,887,216 | 29,082,203 | - | ||||||
Impairment of goodwill | 3,197,391 | 1,139,297 | 398,135,038 | ||||||
Derecognition of goodwill | 453,017 | - | - | ||||||
Loss on warrant liability | 1,608,973 | - | - | ||||||
Stock-based compensation expense | 16,631,898 | 2,835,971 | 189,581 | ||||||
Rescission of warrant exercise expense | - | - | 561,651 | ||||||
Deferred tax (benefit) expense | (13,132,990) | (5,707,323) | 4,996,209 | ||||||
Debt accretion expense | 1,042,663 | 1,209,981 | 1,952,829 | ||||||
Loss on lease termination | - | 58,210 | - | ||||||
Non-cash lease expense | (381,035) | 131,582 | 64,143 | ||||||
Changes in operating assets and liabilities: | |||||||||
Accounts receivable | (173,956,924) | (969,761) | 56,622,133 | ||||||
Accounts receivable - related party | 549,879 | (3,613,885) | 1,454,934 | ||||||
Inventories | 540,770 | 142,701 | (719,107) | ||||||
Prepaid expenses and other current assets | (7,021,010) | (817,297) | (1,419,139) | ||||||
Accounts payable | (8,682,179) | (4,715,101) | 10,018,100 | ||||||
Accounts payable - related party | (2,037,059) | 2,466,536 | (329,155) | ||||||
Accrued arbitration expenses | 47,741,815 | - | - | ||||||
Accrued income tax expense | 25,989,262 | - | - | ||||||
Accrued expenses and other current liabilities | 12,478,227 | 5,845,481 | (1,311,865) | ||||||
Net cash from operating activities | 23,153,807 | 1,256,452 | 50,607,108 | ||||||
Cash flows from investing activities: | |||||||||
Acquisitions of property and equipment | (2,303,897) | (9,496,832) | (14,632,414) | ||||||
Acquired cash in reverse acquisition with Clinigence | - | - | 12,716,228 | ||||||
Cash related to sale of business | (361,325) | - | - | ||||||
Payments for acquisitions of businesses, net of cash acquired | - | (703,893) | - | ||||||
Cash related to deconsolidation of Real Estate Entities | - | (1,039,157) | (2,421,212) | ||||||
Net cash from investing activities | (2,665,222) | (11,239,882) | (4,337,398) | ||||||
Cash flows from financing activities: | |||||||||
Proceeds from lines of credit | 2,261,743 | 2,340,911 | 2,623,479 | ||||||
Proceeds from notes payable | 7,014,999 | 16,952,905 | 815,881 | ||||||
Proceeds from convertible notes | - | 4,909,864 | - | ||||||
Repayments of lines of credit | (2,079,390) | (1,592,714) | (72,055) | ||||||
Repayments of notes payable | (9,969,391) | (16,479,512) | (7,237,094) | ||||||
Repayments of finance leases | (4,628,083) | (3,484,683) | (1,721,224) | ||||||
Proceeds from common stock issuance, net issuance costs | 9,202,500 | - | - | ||||||
Rescission of warrant exercise | - | - | (588,042) | ||||||
Proceeds from exercise of warrants | 2,373,336 | - | 4,119,141 | ||||||
Proceeds from exercise of options | - | - | 644,974 | ||||||
Members' contributions | 3,353,023 | 298,032 | 4,513,867 | ||||||
Members' distributions | (6,437,966) | (5,214,581) | (51,231,657) | ||||||
Net cash from financing activities | 1,090,771 | (2,269,778) | (48,132,730) | ||||||
Net change in cash and cash equivalents | 21,579,356 | (12,253,208) | (1,863,020) | ||||||
Cash and cash equivalents - beginning of the year | 22,002,056 | 34,255,264 | 36,118,284 | ||||||
Cash and cash equivalents - end of the year | $ | 43,581,412 | $ | 22,002,056 | $ | 34,255,264 | |||
Non-GAAP Financial Measures (Unaudited)
EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.
We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.
We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for stock-based compensation, certain defined items of expense, any acquisition-related costs and impairments. Interest expense includes interest on lease liabilities, which is a component of total finance lease cost. A reconciliation of net income to Adjusted EBITDA is included below. Adjusted EBITDA is not intended to serve as an alternative to
Year ended December 31, | |||||||||
2024 | 2023 | 2022 | |||||||
Reconciliation of net income (loss) attributable to Nutex Health Inc. to | |||||||||
Net income (loss) attributable to Nutex Health Inc. | $ | 52,179,168 | $ | (45,786,614) | $ | (424,780,446) | |||
Depreciation and amortization | 18,971,972 | 17,591,572 | 13,131,374 | ||||||
Interest expense, net | 19,932,015 | 16,317,869 | 12,490,260 | ||||||
Income tax expense (benefit) | 14,476,821 | (5,067,084) | 13,090,905 | ||||||
Allocation to noncontrolling interests | (7,176,312) | (5,546,263) | (4,837,514) | ||||||
EBITDA | 98,383,664 | (22,490,520) | (390,905,421) | ||||||
Facility closing costs | - | 217,266 | - | ||||||
Acquisition costs | - | 43,464 | 3,885,666 | ||||||
Loss on warrant liability | 1,608,973 | - | - | ||||||
Stock-based compensation | 16,631,898 | 2,835,971 | 189,581 | ||||||
Rescission of warrant exercise | - | - | 1,243,059 | ||||||
Impairment of assets | 3,887,216 | 29,082,203 | - | ||||||
Impairment of goodwill | 3,197,391 | 1,139,297 | 398,135,038 | ||||||
Adjusted EBITDA | $ | 123,709,142 | $ | 10,827,681 | $ | 12,547,923 | |||
Three months ended | Three months ended | |||||
December 31, 2024 | December 31, 2023 | |||||
Unaudited | Unaudited | |||||
Reconciliation of net income (loss) attributable to Nutex Health Inc. to | ||||||
Net income (loss) attributable to Nutex Health Inc. | $ | 61,695,604 | $ | (31,617,897) | ||
Depreciation and amortization | 5,280,488 | 4,682,724 | ||||
Interest expense, net | 5,052,081 | 4,236,553 | ||||
Income tax expense (benefit) | 8,608,746 | (2,998,554) | ||||
Allocation to noncontrolling interests | (2,195,888) | (2,045,390) | ||||
EBITDA | 78,441,031 | (27,742,564) | ||||
Loss on warrant liability | 536,264 | - | ||||
Stock-based compensation | 14,680,454 | 637,159 | ||||
Impairment of assets | (11,640) | 29,082,203 | ||||
Impairment of goodwill | - | 1,139,297 | ||||
Adjusted EBITDA | $ | 93,646,109 | $ | 3,116,095 | ||
About Nutex Health Inc.
Headquartered in
The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states.
The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups.
Forward-Looking Statements
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended year ended December 31, 2024 under the heading "Risk Factors" in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
View original content:https://www.prnewswire.com/news-releases/nutex-health-reports-fourth-quarter-and-full-year-2024-financial-results-302416172.html
SOURCE Nutex Health, Inc.
FAQ
What was Nutex Health's (NUTX) revenue growth in 2024?
How much did NUTX's arbitration process contribute to 2024 revenue?
What was NUTX's hospital visit growth in 2024?
How did NUTX's net income change in 2024 compared to 2023?
What is NUTX's current cash position and debt level?
